DENTSPLY SIRONA Inc header image

DENTSPLY SIRONA Inc

XRAY

Equity

ISIN null / Valor 31773200

NASDAQ (2025-11-21)
USD 10.58+6.98%

DENTSPLY SIRONA Inc
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

DENTSPLY SIRONA Inc is a global leader in the manufacturing of professional dental products and technologies, working in collaboration with partners to develop innovative solutions for dental professionals worldwide. With a mission to transform dentistry and improve oral health on a global scale, the company is dedicated to empowering dental practices, clinics, laboratories, and distributors to deliver top-quality dental care to patients. DENTSPLY SIRONA's research division plays a key role in driving the development of next-generation dental solutions, reflecting the company's commitment to advancing the field of dentistry.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (03.10.2025):

DENTSPLY SIRONA Inc reported its financial results for the first quarter of 2025, showing a decline in net sales and organic sales compared to the same period last year. Despite these decreases, the company maintained its full-year 2025 outlook and demonstrated improvements in adjusted EBITDA margin, reflecting ongoing transformational initiatives and operational efficiencies.

Net Sales Decline

For Q1 2025, DENTSPLY SIRONA Inc reported net sales of $879 million, a decrease of 7.7% compared to Q1 2024. Organic sales also fell by 4.4%, impacted by a 4.0% decrease in Byte sales.

Profit Margins

The GAAP gross margin remained relatively stable at 53.0%, slightly down from 53.1% in the previous year. On a non-GAAP basis, the adjusted gross margin improved to 56.3%, and the adjusted EBITDA margin expanded to 19.0% from 16.8% year-over-year.

Net Income and Earnings Per Share

GAAP net income for Q1 2025 was $20 million, or $0.10 per share, up from $18 million in Q1 2024. Adjusted earnings per share increased by 3.7% to $0.43.

Operational Highlights

Organic sales were approximately flat excluding the Byte sales impact, with growth observed in two out of three regions. The adjusted EBITDA margin expansion reflects benefits from transformational initiatives and enhanced financial discipline.

Full-Year 2025 Outlook

DENTSPLY SIRONA Inc is maintaining its full-year 2025 outlook, expecting organic sales to decline between 4.0% and 2.0% and adjusted earnings per share to remain within the anticipated range. The company also expects reported sales to increase due to favorable foreign exchange changes.

Cash Flow and Liquidity

The company reported a net increase in cash and cash equivalents of $126 million for Q1 2025, bringing the total to $398 million at the end of the period. Operating cash flow was supported by net income and improvements in working capital.

Summarized from source with an LLMView Source

Key figures

-43.2%1Y
-65.4%3Y
-78.6%5Y

Performance

52.2%1Y
38.6%3Y
36.5%5Y

Volatility

Market cap

2111 M

Market cap (USD)

Daily traded volume (Shares)

4,288,687

Daily traded volume (Shares)

1 day high/low

18.86 / 18.36

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Edwards Lifesciences Corp
Edwards Lifesciences Corp Edwards Lifesciences Corp Valor: 1065343
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.24%USD 85.13
Dyne Therapeutics Inc
Dyne Therapeutics Inc Dyne Therapeutics Inc Valor: 56806425
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
5.27%USD 21.18
Boiron SA
Boiron SA Boiron SA Valor: 487646
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.95%EUR 26.60
Bright Horizons Family Solutions
Bright Horizons Family Solutions Bright Horizons Family Solutions Valor: 19920287
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.62%USD 101.12
Dr Reddy'S Laboratories Ltd
Dr Reddy'S Laboratories Ltd Dr Reddy'S Laboratories Ltd Valor: 1221723
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.07%USD 13.91
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA SCHOTT Pharma AG & Co. KGaA Valor: 128964250
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.66%EUR 18.44
Coloplast A/S
Coloplast A/S Coloplast A/S Valor: 20259063
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.55%DKK 580.20
MannKind Corp
MannKind Corp MannKind Corp Valor: 35935511
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.21%USD 5.03
Essity AB
Essity AB Essity AB Valor: 36851944
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.79%SEK 260.90
Lifco Ab
Lifco Ab Lifco Ab Valor: 111355378
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.18%SEK 342.20